BofA Securities analyst Jason Gerberry lowered the price target on Arrowhead Pharma (NASDAQ: ARWR) to $41.00 (from $46.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE